{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:21:06Z","timestamp":1780600866871,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40801-025-00518-6","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:11:35Z","timestamp":1759471895000},"page":"615-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8458-0986","authenticated-orcid":false,"given":"Manuel Enrique","family":"Machado-Duque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2500-7658","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Gaviria-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-0101","authenticated-orcid":false,"given":"Luis Fernando","family":"Valladales-Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-0936","authenticated-orcid":false,"given":"Jorge Enrique","family":"Machado-Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"issue":"10","key":"518_CR1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/jama.2015.10029","volume":"314","author":"A Menke","year":"2015","unstructured":"Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988\u20132012. JAMA. 2015;314(10):1021\u20139. https:\/\/doi.org\/10.1001\/jama.2015.10029.","journal-title":"JAMA"},{"issue":"10","key":"518_CR2","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/jama.2015.9536","volume":"314","author":"DM Nathan","year":"2015","unstructured":"Nathan DM. Diabetes: advances in diagnosis and treatment. JAMA. 2015;314(10):1052\u201362. https:\/\/doi.org\/10.1001\/jama.2015.9536.","journal-title":"JAMA"},{"issue":"6","key":"518_CR3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.aogh.2015.11.001","volume":"81","author":"H Vargas-Uricoechea","year":"2015","unstructured":"Vargas-Uricoechea H, Casas-Figueroa L. An epidemiologic analysis of diabetes in Colombia. Ann Glob Health. 2015;81(6):742\u201353. https:\/\/doi.org\/10.1016\/j.aogh.2015.11.001. (PubMed PMID: 27108142).","journal-title":"Ann Glob Health"},{"issue":"10085","key":"518_CR4","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/s0140-6736(17)30058-2","volume":"389","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(17)30058-2.","journal-title":"Lancet"},{"issue":"6","key":"518_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fca-2018-0045","volume":"14","author":"RJ Henning","year":"2018","unstructured":"Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018;14(6):491\u2013509. https:\/\/doi.org\/10.2217\/fca-2018-0045.","journal-title":"Future Cardiol"},{"issue":"19","key":"518_CR6","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"4","key":"518_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"key":"518_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol Metab. 2021;46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102.","journal-title":"Mol Metab"},{"issue":"11","key":"518_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"5","key":"518_CR10","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s13300-021-01053-7","volume":"12","author":"C Uzoigwe","year":"2021","unstructured":"Uzoigwe C, Liang Y, Whitmire S, Paprocki Y. Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting. Diabetes Ther. 2021;12(5):1475\u201389. https:\/\/doi.org\/10.1007\/s13300-021-01053-7.","journal-title":"Diabetes Ther"},{"issue":"2","key":"518_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s13300-019-0590-x","volume":"10","author":"B Guerci","year":"2019","unstructured":"Guerci B, Chanan N, Kaur S, Jasso-Mosqueda JG, Lew E. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Ther. 2019;10(2):437\u201349. https:\/\/doi.org\/10.1007\/s13300-019-0590-x.","journal-title":"Diabetes Ther"},{"issue":"3","key":"518_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.diabet.2012.12.005","volume":"39","author":"L Gu\u00e9nette","year":"2013","unstructured":"Gu\u00e9nette L, Moisan J, Breton MC, Sirois C, Gr\u00e9goire JP. Difficulty adhering to antidiabetic treatment: factors associated with persistence and compliance. Diabetes Metab. 2013;39(3):250\u20137. https:\/\/doi.org\/10.1016\/j.diabet.2012.12.005.","journal-title":"Diabetes Metab"},{"issue":"5","key":"518_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.661","volume":"8","author":"JS Franco","year":"2020","unstructured":"Franco JS, Vizcaya D. Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: a systematic review. Pharmacol Res Perspect. 2020;8(5):e00661. https:\/\/doi.org\/10.1002\/prp2.661.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"518_CR14","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2019.4.1588","volume":"17","author":"E Lajthia","year":"2019","unstructured":"Lajthia E, Bucheit JD, Nadpara PA, Dixon DL, Caldas LM, Murchie M, et al. Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series. Pharm Pract (Granada). 2019;17(4):1588. https:\/\/doi.org\/10.18549\/PharmPract.2019.4.1588.","journal-title":"Pharm Pract (Granada)"},{"key":"518_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12954","author":"ME Machado-Duque","year":"2017","unstructured":"Machado-Duque ME, Ram\u00edrez-Riveros AC, Machado-Alba JE. Effectiveness and clinical inertia in patients with antidiabetic therapy. Int J Clin Pract. 2017. https:\/\/doi.org\/10.1111\/ijcp.12954.","journal-title":"Int J Clin Pract"},{"issue":"4","key":"518_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/14656566.2023.2178900","volume":"24","author":"LF Valladales-Restrepo","year":"2023","unstructured":"Valladales-Restrepo LF, S\u00e1nchez-Ram\u00edrez N, Usma-Valencia AF, Gaviria-Mendoza A, Machado-Duque ME, Machado-Alba JE. Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity. Expert Opin Pharmacother. 2023;24(4):535\u201343. https:\/\/doi.org\/10.1080\/14656566.2023.2178900.","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"518_CR17","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140\u201357. https:\/\/doi.org\/10.2337\/dc23-S009.","journal-title":"Diabetes Care"},{"key":"518_CR18","unstructured":"INVIMA. Consulta de registro sanitarios. Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Ministerio de Salud de Colombia. 2024. https:\/\/www.invima.gov.co\/consulta-registros-sanitarios. Accessed cited 2025."},{"key":"518_CR19","doi-asserted-by":"publisher","first-page":"e078242","DOI":"10.1136\/bmj-2023-078242","volume":"385","author":"N Simms-Williams","year":"2024","unstructured":"Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024;385:e078242. https:\/\/doi.org\/10.1136\/bmj-2023-078242.","journal-title":"BMJ"},{"issue":"6","key":"518_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4330\/wjc.v14.i6.329","volume":"14","author":"AK Singh","year":"2022","unstructured":"Singh AK, Singh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol. 2022;14(6):329\u201342. https:\/\/doi.org\/10.4330\/wjc.v14.i6.329.","journal-title":"World J Cardiol"},{"issue":"7","key":"518_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.18553\/jmcp.2022.28.7.740","volume":"28","author":"N Kim","year":"2022","unstructured":"Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, et al. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. J Manag Care Spec Pharm. 2022;28(7):740\u201352. https:\/\/doi.org\/10.18553\/jmcp.2022.28.7.740.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"518_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.clinthera.2022.01.017","volume":"44","author":"R Mody","year":"2022","unstructured":"Mody R, Manjelievskaia J, Marchlewicz EH, Malik RE, Zimmerman NM, Irwin DE, et al. Greater adherence and persistence with injectable dulaglutide compared with injectable semaglutide at 1-year follow-up: data from US clinical practice. Clin Ther. 2022;44(4):537\u201354. https:\/\/doi.org\/10.1016\/j.clinthera.2022.01.017.","journal-title":"Clin Ther"},{"issue":"12","key":"518_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108874","volume":"38","author":"JJ C\u00e1rdenas-Salas","year":"2024","unstructured":"C\u00e1rdenas-Salas JJ, Sierra Poyatos RM, Luca BL, S\u00e1nchez Lechuga B, Modro\u00f1o M\u00f3stoles N, Montoya \u00c1lvarez T, et al. REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: ambispective, multicenter clinical study. Results in the GLP1-experienced cohort. J Diabetes Complicat. 2024;38(12):108874. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108874.","journal-title":"J Diabetes Complicat"},{"key":"518_CR24","unstructured":"INVIMA\u2014Listado de Abastecimiento y desnbastecimiento octubre 2024. Grupo de apoyo de las salas especializadas de comisi\u00f3n revisora. Bogot\u00e1 DC. Colombia2024. https:\/\/www.invima.gov.co\/sites\/default\/files\/medicamentos-productos-biologicos\/Desabastecimientos\/2024\/Establecimientos\/listado_de_abastecimiento_y_desabastecimiento_de_medicamentos_en_seguimiento_octubre_de_2024_-_publicado.pdf. Accessed 22 Oct 2024."},{"issue":"7","key":"518_CR25","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.2337\/dc25-0566","volume":"48","author":"C Tejera-P\u00e9rez","year":"2025","unstructured":"Tejera-P\u00e9rez C. Comment on Kom\u00e9 et al. One Size Does Not Fit All: understanding microdosing semaglutide for diabetes in multidose pens. Diabetes Care. 2025;48(7):e93. https:\/\/doi.org\/10.2337\/dc25-0566.","journal-title":"Diabetes Care"},{"issue":"10148","key":"518_CR26","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/s0140-6736(18)31773-2","volume":"392","author":"PM O'Neil","year":"2018","unstructured":"O\u2019Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637\u201349. https:\/\/doi.org\/10.1016\/s0140-6736(18)31773-2.","journal-title":"Lancet"},{"issue":"4","key":"518_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/s2213-8587(17)30013-x","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsb\u00f8l JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360. https:\/\/doi.org\/10.1016\/s2213-8587(17)30013-x.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00518-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00518-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00518-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:17:12Z","timestamp":1763687832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00518-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["518"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00518-6","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"21 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Bioethics Committee of the Universidad Tecnol\u00f3gica de Pereira (Technological University of Pereira) in the category of risk-free research (Endorsement Code: 25-180324). The ethical principles established by the Declaration of Helsinki were respected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MEMD and JEMA wrote the manuscript; MEMD, AGM, and LFVR designed the research; MEMD, AGM, LFVR, and JEMA performed the research; MEMD analyzed the data. All authors read and approved the final version and agree to be accountable for the work","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Jorge Enrique Machado-Alba, MD, PhD is an Editorial Board member of\n                      Drugs\u2014Real World Outcomes\n                      . Jorge Enrique Machado-Alba, MD, PhD was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The other authors declare no conflicts of interest.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"See protocols.io.\n                      \n                      .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement and data access"}}]}}